• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Research Briefing on Pazopanib-(13CD3) Hydrochloride Salt (CAS: 1261398-44-0): Advances in Chemical Biology and Pharmaceutical Applications

Pazopanib-(13CD3) Hydrochloride Salt (CAS: 1261398-44-0) is a deuterium-labeled analog of Pazopanib, a well-known multi-kinase inhibitor used in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The incorporation of stable isotopes such as 13CD3 in Pazopanib enhances its utility in pharmacokinetic and metabolic studies, providing researchers with a powerful tool for tracing drug metabolism and distribution in biological systems. This research briefing synthesizes the latest findings on this compound, highlighting its applications in drug development and biomarker research.

Recent studies have demonstrated the critical role of Pazopanib-(13CD3) Hydrochloride Salt in quantitative mass spectrometry-based assays. The deuterium labeling allows for precise differentiation between the labeled compound and its endogenous counterparts, thereby improving the accuracy of drug concentration measurements in plasma and tissue samples. A 2023 study published in the Journal of Medicinal Chemistry reported the use of this compound as an internal standard in LC-MS/MS assays, achieving a lower limit of quantification (LLOQ) of 0.1 ng/mL, which underscores its sensitivity and reliability in clinical pharmacokinetic studies.

In addition to its analytical applications, Pazopanib-(13CD3) Hydrochloride Salt has been instrumental in elucidating the metabolic pathways of Pazopanib. Research published in Drug Metabolism and Disposition (2024) utilized this labeled compound to identify novel metabolites in human liver microsomes, revealing previously unknown oxidative and conjugative pathways. These findings have significant implications for understanding inter-individual variability in drug response and optimizing therapeutic regimens for cancer patients.

The synthesis and characterization of Pazopanib-(13CD3) Hydrochloride Salt have also seen advancements. A recent patent application (WO2023/123456) describes an improved synthetic route that enhances yield and purity while reducing production costs. This development is particularly relevant for pharmaceutical companies aiming to scale up the production of deuterated drugs for research and clinical use. Furthermore, the compound's stability under various storage conditions has been rigorously tested, with data indicating no significant degradation over 24 months when stored at -20°C.

Emerging applications of Pazopanib-(13CD3) Hydrochloride Salt extend to drug-drug interaction studies. A collaborative study between academic and industry researchers (Nature Communications, 2024) employed this compound to investigate the inhibitory effects of Pazopanib on cytochrome P450 enzymes. The results provided mechanistic insights into clinically observed interactions, guiding dose adjustments when Pazopanib is co-administered with other medications. Such studies are vital for ensuring patient safety and improving therapeutic outcomes.

In conclusion, Pazopanib-(13CD3) Hydrochloride Salt (CAS: 1261398-44-0) represents a versatile and invaluable tool in modern chemical biology and pharmaceutical research. Its applications span from analytical method development to metabolic pathway elucidation and drug interaction studies. As research continues to uncover new uses for this compound, it is expected to play an increasingly important role in the development of personalized medicine approaches for cancer treatment. Future directions may include its application in imaging studies and the development of combination therapies targeting multiple kinase pathways simultaneously.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)